BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 34297902)

  • 1. Identification and Optimization of a Minor Allele-Specific siRNA to Prevent PNPLA3 I148M-Driven Nonalcoholic Fatty Liver Disease.
    Murray JK; Long J; Liu L; Singh S; Pruitt D; Ollmann M; Swearingen E; Hardy M; Homann O; Wu B; Holder JR; Sham K; Herberich B; Lo MC; Dou H; Shkumatov A; Florio M; Rulifson IC
    Nucleic Acid Ther; 2021 Oct; 31(5):324-340. PubMed ID: 34297902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pnpla3 silencing with antisense oligonucleotides ameliorates nonalcoholic steatohepatitis and fibrosis in Pnpla3 I148M knock-in mice.
    Lindén D; Ahnmark A; Pingitore P; Ciociola E; Ahlstedt I; Andréasson AC; Sasidharan K; Madeyski-Bengtson K; Zurek M; Mancina RM; Lindblom A; Bjursell M; Böttcher G; Ståhlman M; Bohlooly-Y M; Haynes WG; Carlsson B; Graham M; Lee R; Murray S; Valenti L; Bhanot S; Åkerblad P; Romeo S
    Mol Metab; 2019 Apr; 22():49-61. PubMed ID: 30772256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery and Targeting of the Signaling Controls of
    Schwartz BE; Rajagopal V; Smith C; Cohick E; Whissell G; Gamboa M; Pai R; Sigova A; Grossman I; Bumcrot D; Sasidharan K; Romeo S; Sehgal A; Pingitore P
    Cells; 2020 Oct; 9(10):. PubMed ID: 33036387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of a Metabolic, Transcriptomic, and Molecular Signature of Patatin-Like Phospholipase Domain Containing 3-Mediated Acceleration of Steatohepatitis.
    Banini BA; Kumar DP; Cazanave S; Seneshaw M; Mirshahi F; Santhekadur PK; Wang L; Guan HP; Oseini AM; Alonso C; Bedossa P; Koduru SV; Min HK; Sanyal AJ
    Hepatology; 2021 Apr; 73(4):1290-1306. PubMed ID: 33131062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The I148M PNPLA3 polymorphism influences serum adiponectin in patients with fatty liver and healthy controls.
    Valenti L; Rametta R; Ruscica M; Dongiovanni P; Steffani L; Motta BM; Canavesi E; Fracanzani AL; Mozzi E; Roviaro G; Magni P; Fargion S
    BMC Gastroenterol; 2012 Aug; 12():111. PubMed ID: 22898488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatic patatin-like phospholipase domain-containing 3 levels are increased in I148M risk allele carriers and correlate with NAFLD in humans.
    Ericson E; Bergenholm L; Andréasson AC; Dix CI; Knöchel J; Hansson SF; Lee R; Schumi J; Antonsson M; Fjellström O; Nasr P; Liljeblad M; Carlsson B; Kechagias S; Lindén D; Ekstedt M
    Hepatol Commun; 2022 Oct; 6(10):2689-2701. PubMed ID: 35833455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PNPLA3 gene polymorphism and overall and cardiovascular mortality in the United States.
    Wijarnpreecha K; Scribani M; Raymond P; Harnois DM; Keaveny AP; Ahmed A; Kim D
    J Gastroenterol Hepatol; 2020 Oct; 35(10):1789-1794. PubMed ID: 32220085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The rs2294918 E434K variant modulates patatin-like phospholipase domain-containing 3 expression and liver damage.
    Donati B; Motta BM; Pingitore P; Meroni M; Pietrelli A; Alisi A; Petta S; Xing C; Dongiovanni P; del Menico B; Rametta R; Mancina RM; Badiali S; Fracanzani AL; Craxì A; Fargion S; Nobili V; Romeo S; Valenti L
    Hepatology; 2016 Mar; 63(3):787-98. PubMed ID: 26605757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Role of
    Liu M; Park S
    Nutrients; 2024 Apr; 16(8):. PubMed ID: 38674929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PNPLA3 I148M variant in nonalcoholic fatty liver disease: demographic and ethnic characteristics and the role of the variant in nonalcoholic fatty liver fibrosis.
    Chen LZ; Xin YN; Geng N; Jiang M; Zhang DD; Xuan SY
    World J Gastroenterol; 2015 Jan; 21(3):794-802. PubMed ID: 25624712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of PNPLA3 rs738409 G/C gene polymorphism with nonalcoholic fatty liver disease in children: a meta-analysis.
    Tang S; Zhang J; Mei TT; Guo HQ; Wei XH; Zhang WY; Liu YL; Liang S; Fan ZP; Ma LX; Lin W; Liu YR; Qiu LX; Yu HB
    BMC Med Genet; 2020 Aug; 21(1):163. PubMed ID: 32811452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between non-alcoholic steatohepatitis, PNPLA3 I148M genotype and bone mineral density in adolescents.
    Mosca A; Fintini D; Scorletti E; Cappa M; Paone L; Zicari AM; Nobili V; Byrne CD
    Liver Int; 2018 Dec; 38(12):2301-2308. PubMed ID: 30176114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PNPLA3 I148M Polymorphism in Patients with Nonalcoholic Fatty Liver Disease, Obesity and Prediabetes.
    Karamfilova V; Gateva A; Assyov Y; Alexiev A; Savov A; Yaneva N; Ivanova I; Ivanova-Boyanova R; Ivanova R; Vlahova Z; Mateva L; Kamenov Z
    J Gastrointestin Liver Dis; 2019 Dec; 28(4):433-438. PubMed ID: 31826069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. I148M patatin-like phospholipase domain-containing 3 gene variant and severity of pediatric nonalcoholic fatty liver disease.
    Valenti L; Alisi A; Galmozzi E; Bartuli A; Del Menico B; Alterio A; Dongiovanni P; Fargion S; Nobili V
    Hepatology; 2010 Oct; 52(4):1274-80. PubMed ID: 20648474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of PNPLA3 polymorphism on diagnostic performance of various noninvasive markers for diagnosing and staging nonalcoholic fatty liver disease.
    Liu WY; Zheng KI; Pan XY; Ma HL; Zhu PW; Wu XX; Rios RS; Targher G; Byrne CD; Wang XD; Chen YP; Zheng MH
    J Gastroenterol Hepatol; 2020 Jun; 35(6):1057-1064. PubMed ID: 31677195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review article: the emerging role of genetics in precision medicine for patients with non-alcoholic steatohepatitis.
    Carlsson B; Lindén D; Brolén G; Liljeblad M; Bjursell M; Romeo S; Loomba R
    Aliment Pharmacol Ther; 2020 Jun; 51(12):1305-1320. PubMed ID: 32383295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Independent and joint correlation of PNPLA3 I148M and TM6SF2 E167K variants with the risk of coronary heart disease in patients with non-alcoholic fatty liver disease.
    Wu JT; Liu SS; Xie XJ; Liu Q; Xin YN; Xuan SY
    Lipids Health Dis; 2020 Feb; 19(1):29. PubMed ID: 32093693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IL-6/STAT3 axis dictates the PNPLA3-mediated susceptibility to non-alcoholic fatty liver disease.
    Park J; Zhao Y; Zhang F; Zhang S; Kwong AC; Zhang Y; Hoffmann HH; Bushweller L; Wu X; Ashbrook AW; Stefanovic B; Chen S; Branch AD; Mason CE; Jung JU; Rice CM; Wu X
    J Hepatol; 2023 Jan; 78(1):45-56. PubMed ID: 36049612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PNPLA3 I148M and response to treatment for hepatic steatosis: A systematic review.
    Boeckmans J; Gatzios A; Schattenberg JM; Koek GH; Rodrigues RM; Vanhaecke T
    Liver Int; 2023 May; 43(5):975-988. PubMed ID: 36719059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of the rs738409 polymorphism in PNPLA3 with liver damage and the development of nonalcoholic fatty liver disease.
    Hotta K; Yoneda M; Hyogo H; Ochi H; Mizusawa S; Ueno T; Chayama K; Nakajima A; Nakao K; Sekine A
    BMC Med Genet; 2010 Dec; 11():172. PubMed ID: 21176169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.